



# Biotech Daily

Friday January 1, 2016

*Special Edition*

2015: BDI-40 UP 21%; ASX200 DOWN 2%, BIG CAPS UP 17%

*COMPUMEDICS UP 340%, POLYNOVO 318%, GENETIC TECHNOLOGIES 231%  
TISSUE THERAPIES DOWN 83%, MESOBLAST 51%*

The Biotech Daily Top-40 Index (BDI-40) closed 2015 up 21.1 percent compared to the S&P ASX200 falling 2.2 percent, while the three Big Caps of Cochlear, CSL and Resmed (which are not in the BDI-40) climbed 16.9 percent for the year to December 31, 2015.


Twenty-six BDI-40 companies were up in 2015, 13 more than doubled, while 14 fell.

From a low base of \$15 million, Compumedics was the best, adding \$51 million (340%) to a market capitalization of \$66 million. Polynovo ended the year with US FDA approval for its Novosorb wound treatment, up 318.4 percent to \$159 million, followed by Genetic Technologies (230.8%), Pro Medicus (212.8%), Oncosil (183.9%), IDT (179.3%), Atcor (175.0%), Medical Developments (171.8%), Pharmaxis (171.4%) and Ellex (170.0%).

Tissue Therapies led the falls, down 83.3 percent to \$14 million, followed by Mesoblast (50.6%) and Prana (41.8%). Companies demoted from the BDI-40 include GI Dynamics down 87.7 percent and Phosphagenics down 84.2 percent. Also outside the BDI-40, but vying for promotion, were Cogstate up 225 percent, Mayne Pharma (195.6%), MMJ Phytotech (190%), Immuron (184.6%), Dorsavi (111.1%), and Medibio (100%).

On the Nasdaq, Sunshine Heart fell 61.2 percent to \$33 million, followed by Heartware weakening 22.0 percent to \$1,194 million. Biota recovered 6.25 percent to \$102 million.

## BDI-40 v ASX200 Jun 30, 2006 to Dec 31, 2015 - Adjusted



Biotech Daily editor, David Langsam, owns shares in Acrux, Admedus, Benitec, Mesoblast, Nanosonics, Neuren and non-biotechnology stocks. Through Australian Ethical Superannuation he has an indirect interest in other biotechnology companies. These holdings are liable to change: <http://www.australianethical.com.au/who-we-invest-in>.